Sign in
Not yet taking people in SpainPhase 3

Tests oral urea in people with heart failure and low blood sodium

Tests whether oral urea helps adults with heart failure and low blood sodium.

Key facts

Who runs it
Nutricion Medica S.L.
Where
L'hospitalet De Llobregat, Madrid, Málaga, Sevilla, Vigo, and Viladecans, SpainSee the 7 sites
Registry title
UNLOAD-CHF Urea for Normalizing hyponatremia and reducing voLume Overload in Acute and Chronic Heart Failure
Status
Not yet recruiting
Phase
Phase 3
People taking part
210 people, planned
Started
1 Sept 2026
Expected to end
30 Jun 2028
Type of study
Interventional
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure who are retaining fluid and have low blood sodium. It tests oral urea against placebo.

Age
Over 18 years
Sex
All sexes
Disease stage
Heart failure of any cause, with any LVEF, with fluid overload from acute decompensation (oedema, pleural effusion, lung congestion or ascites), needing hospital care or close monitoring in an advanced heart failure unit. Plasma sodium below 135 mmol/L.
Earlier treatment
Long-term furosemide, at least 80 mg by mouth or equivalent. Cannot have taken oral urea in the 3 months before admission or randomisation.
Biomarker or test result
Plasma sodium < 135 mmol/L. NT-proBNP must not be below 350 pg/mL.

Main reasons for not taking part

  • Shock, need for inotropes or ventricular assist devices, or need for intubation at admission
  • Kidney disease with eGFR < 30 ml/min/m2, or plasma urea ≥ 150 mg/dL
  • Child-Pugh C liver cirrhosis
  • Terminal illness, or known allergy, intolerance or contraindication to urea
  • Taking part in another clinical trial, or continuing thiazide treatment

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Heart failure, of any aetiology, regardless of LVEF, requiring hospitalisation or outpatient management with close monitoring in an advanced heart failure unit due to acute decompensation in a hypervolaemic situation, characterised by the presence of oedema, pleural effusion, pulmonary congestion or ascites, clinically demonstrated by chest X-ray or ultrasound
  • Chronic treatment with furosemide, at least 80 mg orally or equivalent, regardless of the use of other diuretics
  • Plasma sodium < 135 mmol/L
  • Individuals over 18 years of age who agree to participate in the study by signing an informed consent form approved by the Ethics Committee

Who cannot take part

  • Treatment with oral urea for 3 months prior to admission/randomisation
  • Patients who will continue treatment with thiazides after inclusion in the study
  • Well-documented previous allergy and/or intolerance and/or contraindication to the use of urea
  • Terminal illness/agony
  • Renal disease with an estimated glomerular filtration rate < 30 ml/min/m2
  • Chronic liver disease in Child-Pugh C liver cirrhosis
  • Blood glucose > 250 mg/dL, or 180-250 mg/dL together with serum sodium of 133-135 mEq/L at the time of admission
  • Plasma urea ≥ 150 mg/dL
  • Clinical instability at admission, defined by: Cardiogenic/distributive shock, with systolic blood pressure < 90 mmHg and mean arterial pressure < 65 mmHg.; Need for inotropes or ventricular assist devices and Need for orotracheal intubation
  • Participation in other clinical trials at the time of randomisation
  • Any patient characteristic that may interfere with adherence to the study protocol or follow-up, such as lack of social support, substance abuse, or the inability of the patient/family member to understand the information and sign the study informed consent form (Appendix I. Information Sheet and Informed Consent Form)
  • NT-proBNP levels < 350 pg/mL
  • History or situation of uraemic encephalopathy on admission

Where in Spain

  • Consorci Sanitari IntegralL'hospitalet De Llobregat, SpainNot yet recruiting
  • Hospital General Universitario Gregorio MarañónMadrid, SpainNot yet recruiting
  • Hospital Universitario Regional de MálagaMálaga, SpainNot yet recruiting
  • Hospital Universitario Virgen De ValmeSevilla, SpainNot yet recruiting
  • University Hospital Virgen Del Rocio S.L.Sevilla, SpainNot yet recruiting
  • Hospital Alvaro CunqueiroVigo, SpainNot yet recruiting
  • Hospital de ViladecansViladecans, SpainNot yet recruiting

About the trial

What the trial wants to find out

To determine whether oral urea (15 g/day or 30 g/day), compared with placebo: Reduces the composite of Cardiovascular mortality and/or the need for hospital care due to heart failure at 90 days. And to determine whether oral urea (15 g/day or 30 g/day), compared with placebo achieves correction of hyponatremia (serum sodium ≥135 mmol/L) at Day 15 and Day 90.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
UNLOAD-CHF Urea for Normalizing hyponatremia and reducing voLume Overload in Acute and Chronic Heart Failure
Plain-language title
Tests oral urea in people with heart failure and low blood sodiumGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
5 November 2026